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Inhibition of formyl peptide receptor in
high-grade astrocytoma by CHemotaxis
Inhibitory Protein of S. aureus
J C Boer1, U M Domanska1, H Timmer-Bosscha1, I G J Boer2, C J C de Haas2, J V Joseph1, F A E Kruyt1,
E G E de Vries1, W F A den Dunnen3, J A G van Strijp2 and A M E Walenkamp*,1
1Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB
Groningen, The Netherlands; 2Department of Medical Microbiology, University Medical Center Utrecht, University of Utrecht,
Heidelberglaan 100, 3584 CX Utrecht, The Netherlands and 3Department of Pathology and Medical Biology, University Medical
Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands
Background: High-grade astrocytomas are malignant brain tumours that infiltrate the surrounding brain tissue and have a poor
prognosis. Activation of formyl peptide receptor (FPR1) on the human astrocytoma cell line U87 promotes cell motility, growth and
angiogenesis. We therefore investigated the FPR1 inhibitor, Chemotaxis Inhibitory Protein of S. aureus (CHIPS), as a potential anti-
astrocytoma drug.
Methods and results: FPR1 expression was studied immunohistochemically in astrocytomas WHO grades I–IV. With intracellular
calcium mobilisation and migration assays, human ligands were tested for their ability to activate FPR1 on U87 cells and on a cell
line derived from primary astrocytoma grade IV patient material. Thereafter, we selectively inhibited these ligand-induced
responses of FPR1 with an anti-inflammatory compound called Chemotaxis Inhibitory Protein of S. aureus (CHIPS). U87 xenografts
in NOD-SCID mice served to investigate the effects of CHIPS in vivo. FPR1 was expressed in 29 out of 32 (90%) of all grades of
astrocytomas. Two human mitochondrial-derived formylated peptides, formyl-methionil-leucine-lysine-isoleucine-valine (fMLKLIV)
and formyl-methionil-methionil-tyrosine-alanine-leucine-phenylalanine (fMMYALF), were potent activators of FPR1 on tumour
cells. Ligand-induced responses of FPR1-expressing tumour cells could be inhibited with FPR1 inhibitor CHIPS. Treatment of
tumour-bearing mice with CHIPS slightly reduced tumour growth and improved survival as compared to non-treated animals
(P¼ 0.0019).
Conclusion: Targeting FPR1 with CHIPS reduces cell motility and tumour cell activation, and prolongs the survival of tumour-
bearing mice. This strategy could be explored in future research to improve treatment results for astrocytoma patients.
Astrocytoma is a malignant neoplasm arising from astrocytes
within the central nervous system. The tumour aggressiveness
ranges from slowly growing low-grade tumours to rapidly growing
high-grade tumours. World Health Organisation (WHO) grade IV
astrocytoma, generally referred to as glioblastoma (GBM), is the
most frequently occurring primary malignant brain tumour in
adults. Median survival after diagnosis is B7 years for patients
with grade II astrocytoma (Louis et al, 2007), whereas the majority
of grade IV astrocytoma patients have a median survival of only
12–15 months (Wen and Kesari, 2008). The current treatment of
astrocytoma consists of surgery followed by radiotherapy and
chemotherapy. However, this strategy does not target tumour cell
migration into surrounding brain tissue, which is a fundamental
feature of astrocytoma and is the major reason for treatment
failure. Therefore, novel drugs that would target tumour spread are
urgently needed.
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Tumour cell migration and leucocyte trafficking have many
similarities (Zlotnik, 2006). Mechanisms involved in leucocyte
migration, such as the expression of G protein-coupled receptors
(GPCRs), could offer important clues for drug development. One
of such GPCR, formyl peptide receptor (FPR1), was initially
identified to mediate leucocyte migration and was characterised
by its ability to bind bacterial-derived chemotactic N-formyl
peptides, such as N-formyl-methionyl-leucyl-phenylalanine (fMLF)
(Schiffmann et al, 1975; Durstin et al, 1994).
Binding of the bacterial peptide fMLF to its receptor FPR1
causes the activation of phagocytic leucocytes, essential for the
innate host defence against microbial infection (Schiffmann et al,
1975). More recently, FPR1 was found to be present on tumour
cells and has been identified as a factor contributing to their
malignant behaviour (Zhou et al, 2005; Huang et al, 2010).
Agonist binding to FPR1 in high-grade astrocytoma cells elicits
a cascade of signal transduction pathways that involve protein
kinase B (Akt), phosphatidylinositol 3-kinase (PI3K), mitogen-
activated protein kinases (MAPK) and the transcription factor
nuclear factor-kB, which are linked with tumour-promoting
cellular processes such as proliferation, migration and angiogenesis
(Vivanco and Sawyers, 2002; Zhou et al, 2005; Yao et al, 2008a).
Mitochondria contain formylated peptides that, analogously to
fMLF, have affinity for FPR1, as shown in promyelocytic HL-60
cells (Rabiet et al, 2005). Moreover, the supernatant of necrotic
astrocytoma cells contains agonists capable of inducing FPR1
activation, followed by a robust intracellular calcium mobilisation
in U87 astrocytoma cells (Zhou et al, 2005). Therefore, we
hypothesised that FPR1 activation in astrocytoma cells can be
induced by mitochondrial peptides present in the necrotic cell
debris, which serve as natural ligands for FPR1.
The FPR1 inhibitor Chemotaxis Inhibitory Protein of S. aureus
(CHIPS) is an anti-inflammatory compound secreted by S. aureus
(de Haas et al, 2004). This virulence factor directly binds to FPR1
and C5a receptor (C5aR), inhibiting neutrophil responses to
bacterial infection (Postma et al, 2004). The potency of CHIPS
to inhibit FPR1, together with the contribution of FPR1 function to
malignant tumour behaviour, prompted us to test CHIPS as a
novel inhibitor of tumour cell activation and migration.
In this study, we investigated FPR1 expression in astrocytomas
WHO grade I–IV. Furthermore, we tested relevant human
mitochondrial ligands for their capacity to activate FPR1 on U87
astrocytoma cells and then studied the possibilities of selectively
inhibiting these effects with CHIPS. Finally, we investigated the
effect of CHIPS treatment in a human tumour-bearing mouse
model.
MATERIALS AND METHODS
Reagents. L-glutamine and gentamicin were obtained from
Invitrogen Life Technologies (Bleiswijk, The Netherlands). fMLF,
ionomycin calcium salt, porcine skin gelatin and Corning
Transwell polycarbonate membrane inserts (8.0 mm pore size)
and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) were purchased from from Sigma-Aldrich (Zwijndrecht,
the Netherlands). Fluorescein isothiocyanate (FITC)-labelled fMLF
and fluo-3 acetoxymethyl ester (Fluo-3-AM) were purchased from
Molecular Probes (Leiden, The Netherlands) and mitochondrial
peptides fMLKLIV and fMMYALF from Isogen Life Science
(de Meern, The Netherlands). Coomassie brilliant blue G-250
was obtained from Bio-Rad Laboratories (Veenendaal, The
Netherlands), Immobilon-P membranes from Millipore Corpora-
tion (Amsterdam, The Netherlands), anti phospho-Akt (Thr308)
(C31E5E) rabbit monoclonal antibody (mAb, no. 2965), anti
phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E)
XP rabbit (mAb, #4370) and rabbit polyclonal antibody against
cleaved caspase-3 (#9661S) were purchased from Cell Signalling
Technology (Leiden, The Netherlands). Polyclonal rabbit antibody
against FPR1 (# ab12990) was purchased from Abcam
(Cambridge, UK), Lumi-lightplus Western blotting substrate and
Pwo DNA polymerase from Roche Diagnostics GmBH (Man-
nheim, Germany). Rabbit polyclonal antibody against glucose
transporter 1 (GLUT-1), horse radish peroxidase (HRP)-labelled
goat anti rabbit and goat anti mouse antibodies were obtained from
Dako (Glostrup, Denmark). Protease inhibitor cocktail EDTA-free
100 and Halt phosphatase from Thermo Scientific (Breda,
The Netherlands). Mammalian Protein Extraction Reagent
(MPER) was obtained from Thermo Scientific (Etten-Leur,
The Netherlands). Quantikine human VEGF ELISA kit was
purchased from R&D systems (Abingdon, UK). The 70 mm pore
size nylon cell strainer was purchased from Beckton Dickinson
(Breda, The Netherlands).
Cells. The human astrocytoma cell line U87 was purchased from
the ATCC (HTB-14). A newly generated cell line was derived from
a 44-year old female patient diagnosed with astrocytoma grade IV.
Primary material was obtained after approval and following the
ethical guidelines of the Institutional Review Board of the UMCG.
Resected tumour tissue was mechanically dissociated, followed by
incubation with trypsin at 37 1C for 15min, repeated pipetting and
filtration through a 70 mM cell strainer to obtain single cells. Cells
were centrifuged, washed with PBS (phosphate buffered saline,
2.7mM KCl, 1.8mM KH2PO4, 137mM NaCl, 10.1mM Na2HPO4,
pH¼ 7.4) and resuspended in culture medium for propagation.
The expression of neuronal and glial markers was confirmed
by immunofluorescence microscopy and Western blotting.
(Supplementary Figure S1A and S1B). Both U87 and the patient
derived cell lines were grown in cell culture flasks pre-coated with
1% gelatin from porcine skin and maintained in Dulbecco’s
modified Eagle Medium high glucose (DMEM-H) supplemented
with 10% foetal calf serum (FCS). The human promonocytic cell
line U937 and its transfected subline U937-FPR were kindly
provided by Dr Eric R Prossnitz (University of New Mexico,
Albuquerque, NM, USA). Cells were maintained in Roswell Park
Memorial Institute medium 1640 (RPMI 1640) containing 10%
FCS, 1% L-glutamine and 10mgml 1 gentamicin. All cell lines
were cultured at 37 1C in a humidified atmosphere with 5% CO2.
Expression of Chemotaxis Inhibitory Protein of S. aureus
(CHIPS) in E. coli. CHIPS was expressed in E. coli, as described
by (de Haas et al, 2004). Briefly, the chp gene was amplified by PCR
on chromosomal DNA of S. aureus (strain Newman) using Pwo
DNA polymerase. The PCR product was cloned into the pTrcHISB
vector (Invitrogen, Bleiswijk, The Netherlands) directly down-
stream of the enterokinase cleavage site. The vector was
transformed into TOP10 E. coli, and recombinant CHIPS was
expressed and purified according to the manufacturer’s instruc-
tions (Invitrogen, Bleiswijk, The Netherlands).
Ligand binding assay. 5 106 U87 cells expressing FPR1 were
incubated for 45min on ice in RPMI 1640 with 1 10 5 M
fluorescent formylated peptide ligand (fMLF-FITC). After incuba-
tion, the cells were washed twice, and the fluorescence of the cells
was measured by flow cytometry (FACSCalibur; Becton Dickinson,
Franklin Lanes, NJ, USA). Data were analysed with WinList
software (Verity Software House, Topsham, ME, USA).
CHIPS-FITC binding. CHIPS was labelled with FITC as
previously described (Postma et al, 2004). FPR1-expressing U87
cells were incubated with increasing concentrations of CHIPS-
FITC (3, 10 and 20 mg ml 1) for 30min at 37 1C in RPMI 1640
containing 0.05% human serum albumin (RPMI/HSA). Subse-
quently, fluorescence of the cells was measured by flow cytometry
and analysed as described above.
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Blocking cellular fMLF-FITC binding with CHIPS. 5 105 U87
or U937-FPR cells were preincubated with RPMI 1640 medium
only or with different CHIPS concentrations (1 and 100 mgml 1)
for 15min at 4 1C. Subsequently cells were incubated for 45min at
4 1C in RPMI 1640 medium with 5 10 6 M (U87) or 10 7 M
(U937-FPR) fluorescent formylated peptide ligand (fMLF-FITC).
After incubation, the cells were washed twice and fluorescence was
measured by flow cytometry as described above.
Ca2þ mobilisation assay. 5 106 U87, U937-FPR and the
patient-derived cells were centrifuged twice (10min, 250 g, at
4 1C) in RPMI/BSA and resuspended in 1ml of RPMI/BSA.
Intracellular calcium was labelled by adding 2 ml Fluo-3-AM to the
cell suspension. Cells were incubated for 20min at room
temperature on a shaking table, centrifuged twice and suspended
in RPMI/BSA. Thereafter, patient-derived cells were incubated
with 1 mgml 1 CHIPS and U87 and U937-FPR1 cells were
incubated with 0, 0.01, 0.1 or 1 mgml 1 CHIPS for 15min at room
temperature. Samples were analysed by flow cytometry as
described above. First, the background fluorescence of cells was
measured. Subsequently, cells were stimulated with fMMYALF,
fMLKLIV or fMLF peptides in concentrations ranging from 10 8–
10 5M for U87, U937-FPR and patient-derived cells, or with
ionomycin as a positive control. Data were calculated as the
percentage of maximal calcium mobilisation using the following
formula: ((MFsample bgFsample)/(MFmax bgFmax)) 100%, in
which MF¼mean fluorescence with stimulation and bgF¼
background fluorescence without stimulation. For the maximal
MF (MFmax), the MF value of cells stimulated with the highest
concentration of stimulus was used.
Chemotaxis assay (Transwell). Transwell inserts with 8mm pores
were coated with 50 mgml 1 collagen type I and incubated for 1 h
at 37 1C. Transwell inserts and lower wells were blocked with 1%
BSA/PBS overnight at 4 1C; thereafter, blocking medium was
removed and lower wells were loaded with 300 ml of fMLF,
fMMYALF or fMLKLIV in DMEMþ 0.5% BSA in concentrations
ranging from 10 7 M to 10 10 M.
U87 or U937-FPR1 cells were serum starved for 2 days. All steps
were performed respectively in serum-free DMEM-H and RPMI
1640 medium. After this, 6 105 cells per ml were harvested and
incubated for 15min with control medium or 10 mgml 1 of
CHIPS medium. Subsequently, 1 105 cells per well in 150 ml
serum-free DMEM-H or RPMI 1640 medium were loaded at the
top of Transwell inserts.
Cells were allowed to migrate towards concentrations of fMLF
or serum-free DMEM-H (U87) or fMLF, fMMYALF, fMLKLIV or
serum-free RPMI 1640 medium (U937-FPR1) for 4.5–5.5 h at
37 1C. After migration, the top surface of the Transwell inserts was
cleaned with a cotton swap wetted in PBS. The cells on the bottom
surface of the Transwell insert were fixed with 75% methanol/25%
acidic acid for 20min and stained with 0.25% Coomassie blue in
45% methanol/10% acetic acid for 20min. Excessive staining of
Coomassie blue was removed by washing the Transwell with demi
water. Migrated cells were identified under the microscope at 40
magnification by counting 10 fields of view in the middle of the
filter from left to right.
Immunoblotting. Western blot analysis of Akt, phosphorylated
Akt (phospho-Akt) and phosphorylated extracellular signal-
regulated kinases 1 and 2 (phospho-ERK1/2) was performed.
U87 cells (1 106) were seeded and starved for 24 h, subsequently
cells were preincubated with culture medium or with 1mgml 1
CHIPS for 20min at room temperature. Thereafter, cells were
treated with buffer or different concentrations of fMLF (10 5 M,
10 7 M and 10 8 M) for 30min. Cells were then lysed in MPER
including 1 : 100 protease and 1 : 100 phosphatase inhibitors,
sonicated for 3 s and boiled for 5min. Immunoblot analysis of
phosphorylated ERK1/2 and Akt and total Akt was performed. Cell
lysates were prepared with sample buffer (25mM Tris–HCl, 5%
glycerol, 1% SDS, and 0.05% bromophenol blue, pH¼ 6.8).
Proteins were separated on 10% polyacrylamide gel (SDS-PAGE)
and transferred onto Immobilon-P membranes. The membranes
were blocked by incubation in tris-buffered saline (TBS) with
0.01% Tween-20 (TBST) and 5% BSA for 3 h at room temperature
and then incubated overnight at 4 1C with primary antibodies
against Akt, phospho-Akt and phospho-ERK1/2 in TBST. After
incubation with a horseradish peroxidase–conjugated secondary
antibody, the protein bands were detected. Enhanced chemilumi-
nescence with Lumi-lightplus was used for final signal detection.
MTT assay. U87 cells (4000 cells per well) were plated in 96-well
plates in 200 ml of the culture medium. After 1 h, fMLF, fMLKLIV
or fMLALF (0, 10 5 M,10 6 M, 10 7 M, 10 8 M or 10 9 M) was
added to each well. After 1, 2, 3, 4, 5 or 6 days of incubation with or
without fMLF, cell proliferation was assessed by MTT assay as
described previously (de Vries et al, 1989).
Enzyme linked immunosorbent assay (ELISA). U87 cells
(0.4 106 per well) were seeded in a 6-well plate and preincubated
with culture medium or with 10mgml 1 CHIPS for 15min. Cells
were treated with fMLF (10 7 M) for 24 h, supernatant was
collected, frozen for VEGF-A analyses and cell numbers were
counted. Quantification of VEGF-A protein by ELISA was
performed by using the Quantikine Human VEGF ELISA kit
according to the manufacturer’s instructions. Results were
calculated as pg of VEGF-A per 106 cells and displayed as
normalised values against control (100%) with standard deviations.
Animal model. Male, nonobese diabetic (NOD)/severe combined
immune deficient (SCID) mice (6–8 weeks old) were purchased
from Harlan Laboratories (Horst, The Netherlands). Fourteen mice
were preirradiated with 2Gy and subcutaneously implanted in the
dorsal flank with 5 106 U87 cells in 100 ml PBS. Animals were
randomly divided into a treatment group and a control group.
Starting from day one after tumour cell injection, the animals
designated to the treatment group received daily intraperitoneal
injections with 1.2mg kg 1 CHIPS (in a total volume of 100 ml
PBS) and animals assigned to the control group received PBS
intraperitoneally in an equal volume. Tumour size was calculated
with the formula: Lw2/2, where L represents the length of the
tumours in millimetres and w the width in millimetres. The
animals were killed after they reached the humane endpoint
(tumour size 42 cm3), and the tumours were excised, dissected
into two pieces, snap frozen or formalin-fixed and paraffin-
embedded.
5mm thick sections of paraffin-embedded tumours were
subjected to haematoxylin and eosin (H&E) staining and
immunohistochemistry was performed to visualise cleaved cas-
pase-3 as an apoptotic marker. All experimental procedures were
approved by the Institutional Animal Care and Use Committee
(IACUC) and conducted in accordance with institutional ethical
regulations for experimental animal care.
Human tissue collection. 4mm cryosections of brain tumour
specimens of 32 patients diagnosed between 2007 and 2010 with
grade I–IV astrocytoma were retrieved from the tissue bank at the
Department of Pathology of the University Medical Center
Groningen. Tumours were histologically classified with H&E
staining according to the criteria of the WHO (Louis et al,
2007). Tissue samples with representative histological character-
istics and a sufficient amount of tissue for analyses were included.
Tumour tissues were numerically tagged, based on a national
coding system. According to Dutch law, no further Institutional
Review and Board approval was required (www.federa.org). Eight
pilocytic astrocytomas WHO grade I, 8 diffuse astrocytomas WHO
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grade II, 8 anaplastic astrocytomas WHO grade III and 8
astrocytoma WHO grade IV were stained for FPR1 expression.
Immunohistochemistry and staining evaluation. Both paraffin-
embedded xenografts from the animal study and frozen human
tissues were stained immunohistochemically according to standard
protocols. The paraffin-embedded tissue was first deparaffinised
with xylol, followed by ethanol and transferred to citrate buffer
pH¼ 6.0, heated for 15min at 95 1C and cooled to RT. Following
steps were the same for frozen and paraffin-embedded specimens.
Slides were washed with PBS, blocked with 0.33% H2O2/PBS buffer
for 30min at room temperature and washed again with PBS.
Subsequently, the sections were incubated for 1 h at room
temperature with polyclonal primary antibodies against cleaved
caspase-3, GLUT-1 or FPR1 diluted in 1% BSA/PBS. Tumour
sections were then washed with PBS and incubated with
peroxidase-coupled goat antirabbit secondary antibody in 1%
BSA/PBSþ 1% AB serum for 30min. After washing with PBS, the
slides were incubated with peroxidase-coupled antigoat tertiary
antibody in 1% BSA/PBSþ 1% human AB serum for 30min
followed by 3,30-diaminobenzidine (DAB) treatment for 10min
and rinsed with tap water. Counter staining was performed with
heamatoxylin for 2min and washed with tap water. Paraffin-
embedded U937-FPR cells served as positive control for FPR1
staining. For all sections, omission of the primary antibody served
as a negative control.
Staining evaluation was performed by double-blind scoring
using Olympus WH10 -H/22 grid by scoring on high power field
(ocular 10 and objective 40 ). Quantitative analysis was
performed by calculating the percentage of positive cells on three
high magnification fields per tumour slide. Subsequently, the
antigenic load was calculated as described previously (Kuijlen et al,
2006), by multiplying the percentage of positive cells by their
semiquantitative score. Semiquantitative score ranged in scale from
0 to 4, defined as 0 when no staining, 1 as low intensity staining, 2
as moderate staining, 3 as high intensity staining and 4 as
exceptionally intense staining.
For the evaluation of cleaved caspase-3 levels in U87 xenografts,
a distinction was made between hypoxic and normoxic areas. As
hypoxic areas strongly correlate with the expression of hypoxia
marker GLUT-1 (Macheda et al, 2005; Liao et al, 2007), the regions
located adjacently to the necrotic areas were defined as hypoxic
zones and positive for GLUT-1. The normoxic areas were defined
as the regions surrounding the hypoxic areas containing viable cells
and no GLUT-1 expression (data not shown). Both normoxic and
hypoxic areas were analysed (Sie et al, 2009).
Statistical analyses. All statistical analysis were performed with
GraphPad Prism 5 (GraphPad Prism Software Inc., San Diego, CA,
USA). Statistical significance was set at Po0.05. Kruskal–Wallis
one-way analysis of variance was used (followed by Dunn’s
multiple comparison post-test) to assess differences in medians of
antigenic load, percentage of positive cells between tumour grades.
Data are expressed as median with confidence interval (CI) of 95%.
A non-parametric Student’s t-test was performed to asses
differences in VEGF-A expression. Data analyses on animal
survival was performed using a log-rank (Mantel–Cox) test.
RESULTS
FPR1 is expressed in all grades of astrocytoma specimens. FPR1
expression was observed in all astrocytomas except for one
pilocytic astrocytoma (WHO grade I), one diffuse astrocytoma
(WHO grade II) and one glioblastoma (WHO grade IV). Low
grade diffuse astrocytomas are often characterised by fibrillary
astrocytes with irregular and elongated nuclei embedded in a
fibrillary matrix (Miller and Perry, 2007). FPR1 expression in grade
I astrocytomas was less pronounced on the cell membrane, whereas
it was highly expressed in the fibrillary structures (Figure 1A). In
contrast, on grade-II astrocytoma specimens, mainly the mem-
brane FPR1 expression was observed, mostly with intermediate
staining intensity (Figure 1B). In higher grade astrocytomas with
bulky cytoplasm, a weak cytoplasmic and strong perinuclear
staining was observed (Figure 1C and D). In grade I and II
astrocytomas, 470% of tumour cells were FPR1-positive with a
homogeneous cytoplasmic staining pattern with moderate to high
staining intensity (Figure 1A and B). In grade III astrocytomas
(Figure 1C), 70% of tumour cells were FPR1-positive, but the
expression pattern was less homogeneous, although with high
intensity. In grade IV astrocytomas, 40% of tumour cells were
FPR1-positive. One grade-IV astrocytoma showed exceptionally
high staining intensity, whereas the other seven showed strong
positivity. The distribution of the staining throughout the tissue
was heterogeneous (Figure 1D). The percentage of positive cells in
grade IV (33%) astrocytomas was lower (Po0.05) than grade I
(59%) and grade III (63%) astrocytomas (Figure 1E). The antigenic
load of grade IV astrocytomas was also lower compared with other
grades. However, only the difference in antigenic load between
grade III and grade IV astrocytomas was significant (Po0.05).
fMLF and CHIPS bind to FPR1-expressing U87. With the FPR1
ligand binding assay, we showed that fMLF-FITC binds to the
FPR1 expressed on U87 (Figure 2A). We subsequently performed
the CHIPS-FITC binding assay and found a dose-dependent
binding of CHIPS-FITC to U87-FPR1-expressing cells (Figure 2B).
CHIPS blocks fMLF-FITC binding to U87 and U937-FPR1
cells. We investigated the ability of CHIPS to block fMLF-FITC
binding to FPR1 on U87 and U937-FPR cells. Preincubation with 1
and 100 mgml 1 CHIPS resulted in dose-dependent inhibition of
fMLF-FITC binding on U937-FPR cells (Figure 2C). In U87 cells,
100 mgml 1 of CHIPS resulted in 81±16% inhibition of fMLF-
FITC binding, whereas this effect was not observed after
preincubation with 1 mgml 1 CHIPS (Figure 2D).
CHIPS inhibits formylated peptide-induced calcium mobilisa-
tion. The hallmark of chemokine receptor activation is a rapid and
transient increase in the free intracellular calcium level upon ligand
binding. This signalling pathway was used to examine whether
CHIPS-FITC not only binds FPR1, as demonstrated with the
CHIPS-FITC binding assay, but also inhibits the activation by its
natural ligand fMLF and mitochondrial peptides fMMYALF and
fMLKLIV. U87 cells responded to increasing amounts of fMLF in a
dose-dependent manner with intracellular calcium mobilisation
(Figure 3A, control line). We could decrease calcium mobilisation
up to 60% with 1 mgml 1 CHIPS in U87 cells compared with
control cells (Figure 3A). Similarly, U937-FPR cells showed
intracellular calcium release following stimulation with fMLF
(Figure 3B) and with both mitochondrial peptides fMLKLIV
(Figure 3C) and fMMYALF (Figure 3D). Treatment with
increasing CHIPS concentrations caused a dose-dependent inhibi-
tion of calcium mobilisation (Figure 3B–D). Finally, we used
patient-derived cells that responded in a dose-dependent manner
with intracellular calcium release. This could be decreased up to
70% with 1 mgml 1 CHIPS (Supplementary Figure 1).
Overall, with the intracellular calcium mobilisation assay, we
showed that not only fMLF, but also fMLKLIV and fMMYALF are
agonists for FPR1 as demonstrated in both U937-FPR1 and U87
cells. Moreover, CHIPS can potently inhibit FPR1-mediated
calcium mobilisation in U937-FPR, U87 and patient-derived cell
lines.
CHIPS inhibits formylated peptides-induced migration of U87
and U937-FPR1 cells but not proliferation of U87 cells. We
investigated the ability of CHIPS to inhibit the fMLF, fMMYALF
and fMLKLIV-induced migration and proliferation of U87 and
BRITISH JOURNAL OF CANCER Inhibition of FPR1 in high-grade astrocytoma by CHIPS
590 www.bjcancer.com |DOI:10.1038/bjc.2012.603
U937-FPR cells in a migration and proliferation assays,
respectively.
CHIPS inhibited up to 81% of U937-FPR cells migrating towards
fMLF (Figure 4A), whereas chemotaxis towards DMEM/0.5% BSA
was not affected (data not shown). At 10mgml 1, CHIPS inhibited
83% of U937-FPR cells migrating towards fMMYALF (10 10–
10 7 M) (Figure 4B) and 80% of U937-FPR cells towards fMLKLIV
(10 10–10 7 M) (Figure 4C). The migration of U87 cells towards
fMLF (10 7 M) was 2.5-fold higher relative to the control medium
(Figure 4D). Ten mgml 1 of CHIPS completely abolished the
migration of U87 cells towards 10 7M fMLF (Figure 4D). However,
formylated peptides did not induce the proliferation of U87 cells
with formylated peptides (data not shown).
CHIPS inhibits phosphorylation of key elements in the down-
stream pathway of FPR1. The pronounced effects of formylated
peptides on calcium mobilisation and cell migration and their
inhibition by CHIPS in U87 astrocytoma cells encouraged us to
investigate the downstream FPR1 pathway in more detail. Western
blot analysis showed that increasing concentrations of fMLF
induced the activation of Akt and ERK1/2 in U87 astrocytoma cells
(Figure 5A, lanes 2–4). Akt and ERK1/2 phosphorylation were
inhibited by CHIPS (Figure 5A, lanes 5–7).
CHIPS inhibits the upregulation of VEGF-A in fMLF-stimu-
lated U87cells. We investigated the ability of U87 cells to excrete
VEGF-A upon stimulation with fMLF and tested whether this
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Figure 1. Specimens of human astrocytoma grades I–IV, immunohistochemically stained for FPR1, percentage of positive cells and antigenic
load. Micrographs A–D show astrocytic tumours with WHO grades I–IV, respectively. In the low-grade tumours (A and B), diffuse staining can be
observed. In the high-grade tumours (C and D), the staining intensity is much less homogeneous. Bars¼100mm. (E) Percentages of positive
tumour cells in the various grades of astrocytic tumours (dark line in the box refers to the median, whiskers indicate the 95% CI). The lowest
percentage relative to the other three grades is found in glioblastomas (*Po0.05). (F) Antigenic load, the glioblastoma group has the smallest
values relative to lower grades (*Po0.05).
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could be inhibited by CHIPS. The levels of VEGF-A excretion
reached by control cells was 5174 pg±1323 per 106 cells; the
average value of control cells was set at 100%. After 24 h of
incubation with fMLF, U87 cells showed on an average, 25±9%
increased excretion of VEGF-A compared with that of control. In
cells preincubated with CHIPS, fMLF could induce only 8±3% of
VEGF-A excretion (Po0.04) compared with that of control
(Figure 5B).
In vivo inhibition of tumour growth by CHIPS. To test the
in vivo effects of CHIPS, we subcutaneously implanted U87 cells in
NOD-SCID mice. Animals treated with CHIPS showed slight
reduction in tumour volume (Figure 6A). CHIPS-treated mice
exhibited a 50% survival of 45 days, whereas untreated animals
showed a 50% survival of 41 days. Median survival of treated
animals was higher than untreated animals (P¼ 0.0019)
(Figure 6B).
Cleaved caspase-3 expression on animal specimens. We inves-
tigated the effects of CHIPS treatment on the induction of
apoptosis by analysing the expression of cleaved caspase-3 in U87
xenografts. Within one and the same tumour, normoxic and
hypoxic (Glut1-positive) areas can be distinguished. Between these
areas, significant differences were found in the percentages of
cleaved caspase-3 positive cells in treated (normoxic 1.2% and
hypoxic 32.1%) and untreated (normoxic 0.6% and hypoxic 24.5%)
animals. When comparing normoxic tumour areas between treated
and untreated animals, only a small, but significant difference in
the percentage of cleaved caspase-3-positive cells was found
(treated 0.6%, untreated 1.2% (P¼ 0.026)) (Figure 6D). Between
the treated and untreated group, no significant differences were
observed in the hypoxic area. These results indicate that CHIPS
treatment may increase apoptosis induction.
DISCUSSION
In this study, we investigated FPR1 as an attractive molecular
target for the development of novel, urgently needed antiastrocy-
toma therapeutics. Moreover, we explored the potency of CHIPS in
inhibiting FPR1-mediated cellular responses in established astro-
cytoma cell line U87, a primary patient-tumour derived cell line
and in a human xenograft mouse model.
Our immunohistochemical analysis showed high FPR1 expres-
sion in all grades of astrocytomas (I-IV). Despite that relevance
for FPR1 targeting is likely to be greater in higher grade
astrocytomas defined by necrotic areas (Louis et al, 2007), low
grade tumours can also acquire angiogenic profiles comparable
with glioblastomas (Sie et al, 2010). This indicates that antagonists
of FPR1 could be a valuable treatment option for all grades of
astrocytoma patients and might be of relevance also for low grade
astrocytomas, especially when their location precludes complete
resection (Suchorska et al, 2011).
In this study, we found that mitochondrial peptides fMMYALF
and fMLKLIV, that are normally released from necrotic cells,
exhibit FPR1-mediated calcium flux on FPR1-transfected U937 cell
line, but also on U87. This shows for the first time that
mitochondrial peptides released by necrotic cells serve as human
ligands for FPR1 expressed on human astrocytoma cells. In
addition, we demonstrated that the patient-derived astrocytoma
grade IV cell line expressed functional FPR1, as we could stimulate
calcium mobilisation with fMLF and inhibit this with CHIPS. This
confirms the potential clinical relevance of our findings.
Calcium mobilisation initiated by GPCR activation leads to the
induction of cell migration. Indeed, in a study of Yao et al (2008b),
FPR1 present on CD133þ astrocytoma stem cells could be
activated by bacteria or host-derived chemotactic agonists and lead
to intracellular calcium mobilisation and tumour cell chemotaxis.
Consequently, in our study, CHIPS treatment inhibited the
migration on both U87 astrocytoma cells and U937-FPR cells.
Taken together, these results indicate that CHIPS is a promising
agent to inhibit FPR1 activation on human astrocytoma cells and
decrease cell migration, which is an important biological feature of
high grade astrocytomas.
The first study investigating the effect of FPR1 inhibition on
tumourigenicity of U87 astrocytoma cells was performed in an
immunodeficient mouse model. In this model, short interfering
RNA (siRNA) against FPR1 markedly reduced the tumourigenic
potential of U87 cells (Zhou et al, 2005). This study provided a
rationale for targeting the FPR1 in astrocytoma models; however,
applying these results in the clinical practice remains challenging
due to the problems with delivering siRNA to the tumour cells. In
our study, we tested CHIPS, administered intraperitoneally, for its
potential to inhibit U87 tumour growth in NOD-SCID mice.
Although biological effects in terms of differences in tumour
volumes could be observed, these were not significant. Notably,
animals in the control group reached the human endpoint earlier
compared with treated animals (P¼ 0.0019), proving that CHIPS
treatment in vivo prolongs the survival of U87 tumour-bearing
mice.
CHIPS is very selective, as it does not affect other chemoat-
tractant receptors present on neutrophils such as the FPR-like 1,
complement factor 3a receptor (C3aR), interleukin (IL) 8 receptor
a (IL-8RA) and -b (IL-8RB), leukotriene B4 (LTB4) receptors, and
the platelet activating factor (PAF) receptor (Postma et al, 2004).
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Figure 2. fMLF and CHIPS binding to FPR1 on U87 astrocytoma cell
line. (A) Mean fluorescence intensity of FPR1-expressing U87 cells
incubated with fMLF-FITC (continuous black line) and control-stained
cells (grey histogram). (B) Mean fluorescence intensity of U87 cells
incubated with 3 mgml1 CHIPS-FITC (dashed line), 10mgml1 CHIPS-
FITC (continuous grey line) and 20mgml 1 CHIPS-FITC (continuous
black line) and baseline staining (grey histogram). (C and D) Blocking of
fMLF-FITC binding to U87 and control cells U937-FPR by preincubating
cells with CHIPS. Graphs depict mean fluorescence intensity of U87
(C) and U937-FPR (D) cells when preincubated with 1 mgml 1 CHIPS
(dotted line) or 100mgml 1 CHIPS (dashed line).
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H and boc-PLPLP, the affinity and the potency of CHIPS to bind
and block FPR1 is 1000-fold higher (Haas et al, 2004a).
The pharmacokinetics and toxicity of CHIPS as an anti-
inflammatory drug were investigated in a small phase 1 study. In
that study, circulating anti-CHIPS antibodies induced toxicities
upon intravenous administration of CHIPS due to pre-existing
antibodies (Haas et al, unpublished data). As the active site for
inhibition of FPR1 is located at the N-terminus and is not
dependent on 3D-structural conformations, we recently con-
structed a 6-amino-acid N-terminal peptide that displays CHIPS
activity. Although the peptide is less potent than CHIPS, it was still
able to inhibit fMLF-induced neutrophil response (Haas et al, 2004b).
Therefore, it represents a good candidate for further development as
a clinical FPR1 inhibitor. The development of peptides can easily
overcome problems with antigenicity, and peptidomimetics can open
the way to enhanced stability in such peptides.
Targeting FPR1 with CHIPS has a relevant clinical rationale due
to its interaction with other pathways involved in shaping the
aggressive phenotype of glioblastoma. For example, the cross-talk
of FPR1 with epidermal growth factor receptor (EGFR) exacerbates
the malignant properties of tumour cells like chemotaxis and
proliferation. Moreover, knocking down both receptors yielded to
superior effects compared with the depletion of either one (Huang
et al, 2007). FPR1 activation was also shown to affect VEGF-A and
interleukin 8 (IL-8) production by glioblastoma cells after
intracranial implantation in nude mice, as tumours formed by
cells with silenced FPR1 showed less active angiogenesis, lower
expression of both angiogenic factors and reduced tumour volumes
(Yao et al, 2008a). Although we could not find any in vitro
differences in fMLF-induced U87 cell proliferation as compared
with controls, we did find an inhibitory effect of CHIPS on VEGF-
A excretion in fMLF-induced U87 cell line. This interaction
remains particularly interesting in the context of a recent Food and
Drug Administration (FDA) approval of bevacizumab (mono-
clonal antibody against VEGF-A) for the treatment of recurrent
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Figure 3. Inhibitory effects of CHIPS on formylated peptides-induced calcium mobilisation in U87 and U937-FPR cell lines. (A) Inhibition of
intracellular calcium mobilisation by CHIPS in U87 cells stimulated with fMLF. (B) Inhibition of intracellular calcium mobilisation by CHIPS in U937-
FPR cells stimulated with fMLF (C) with fMLKLIV and (D) fMMYALF. Data are displayed as percentage of maximal calcium mobilization.
Abbreviation: Conc, concentration.
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Figure 4. Inhibitory effects of CHIPS on formylated peptides-induced cell migration in U87 and U937-FPR cell lines. (A) The inhibition of cell
migration by 10 mgml 1 CHIPS in U937-FPR cells stimulated with fMLF (107 M) (B) with fMMYALF and (C) with fMLKLIV peptides (10 10–107 M).
(D) Inhibition of cell migration by 10mgml1 CHIPS in U87 cells stimulated with 107 M fMLF. Data are presented as percentage of migrated cells

































Figure 5. Inhibitory effects of CHIPS on fMLF-induced phosphorylation of Akt, ERK1/2 and total Akt (Western blot) and on VEGF-A excretion
(ELISA) in U87 cells (A) Representative immunoblot showing the effects of CHIPS on fMLF-induced phosphorylation of Akt, ERK1/2 and total Akt
when incubated with fMLF in U87 cells. (B) Levels of VEGF-A protein in supernatants of U87 cells. Cells were preincubated with or without
10mgml 1 CHIPS and treated with fMLF (10 7 M) or culture medium (control) for 24 h. Cells preincubated with CHIPS, produced significantly
lower VEGF-A excretion upon fMLF treatment compared with fMLF-treated cells without CHIPS preincubation (*Po0.04).
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two phase II clinical trials, which showed that bevacizumab
reduced tumour size in part of the astrocytoma patients
(Vredenburgh et al, 2007; Friedman et al, 2009). At the same
time, controversies arose, based on a study in 37 patients
suggesting that this antiangiogenic drug may alter the recurrence
pattern of malignant gliomas (Norden et al, 2008). Anti-VEGF
therapy can facilitate co-option of normal vasculature and tumour
invasion, potentially leading to a more aggressive tumour
phenotype (Rubenstein et al, 2000; Kunkel et al, 2001; Du et al,
2008). To improve current antiangiogenic therapy in astrocytoma
and potentially other tumours, it will be crucial to identify
pathways that simultaneously block perivascular invasion as well as
angiogenesis.
In summary, mitochondrial peptides present in necrotic tumour
material serve as activating ligands for FPR1 on tumour cells.
Moreover, CHIPS specifically inhibits cell activation and migration
via FPR1 on U87 astrocytoma cells and increases the survival of
U87-tumour bearing mice. In addition, FPR1 is present on all
grades of human astrocytoma and induces calcium mobilisation in
a patient-derived astrocytoma cell line when stimulated with fMLF.
We conclude that this receptor constitutes a clinically relevant
target. Therefore, further development of CHIPS derivatives might
well provide a major contribution to current astrocytoma therapy.
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